

Synthetic Human Enfuvirtide

Catalog No.	CRE109A	Quantity:	90 mg
	CRE109B		900 mg
	CRE109C		1.8 g

Alternate Names: Human Immunodeficiency fusion inhibitor

Description: Enfuvirtide also called human immunodeficiency fusion inhibitor blocks HIV's ability to infect healthy CD4 cells. It can reduce the amount of HIV in the blood and increase the number of CD4 cells. Enfuvirtide operates by disrupting the HIV-1 molecular machinery at the final phase of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide mimics components of the HIV-1 fusion apparatus and displace them, preventing normal fusion. HIV attaches to the host CD4+ cell receptor using the viral protein GP120; upon binding, GP120 deforms allowing the viral protein GP41 to insert itself into the host cell's plasma membrane. Entry inhibitors bind to GP41 preventing the formation of an entry pore for the capsid of the virus, keeping it out of the cell. It has a molecular formula of $C_{204}H_{301}N_{51}O_{64}$.

Molecular Weight: 4.491 kDa

Formulation: Lyophilized from a sterile filtered solution without additives

Purity: > 98% by RP-HPLC

Amino Acid Sequence: CH_3CO -Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH₂

Reconstitution: **Centrifuge vial prior to opening.** Product is soluble in water at a concentration of 0.5 mg/mL.

Storage & Stability: Upon receipt, store desiccated at -20 °C to -80 °C. Reconstituted protein is stable for 1 week at 2-4 °C. For long term storage, add 0.1% carrier protein (HSA or BSA), aliquot and store at -20 °C to -80 °C for up to one year. **Avoid repeated freeze-thaw cycles.**

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

